PMID: 11918535Mar 29, 2002Paper

Magnetic resonance imaging of femoral marrow predicts outcome in adult patients with acute myeloid leukaemia in complete remission

British Journal of Haematology
Shojiro Takagi, Osamu Tanaka

Abstract

Accurate assessment of residual disease is important for the prediction of outcome in patients with acute leukaemia in complete remission (CR). To investigate whether abnormalities on magnetic resonance (MR) images of femoral marrow in adult patients with acute myeloid leukaemia (AML) in CR can predict outcome, 28 newly diagnosed patients with AML underwent MR imaging when bone marrow aspiration or biopsy was performed to verify the state of CR after induction therapy. MR abnormalities on short TI (inversion time) inversion recovery (STIR) techniques persisted in all four patients who did not achieve CR. In 13 CR patients abnormalities on STIR images resolved, to result in normal appearance at the time CR was achieved. All 13 patients remained in CR for 3-104 months (median, 73 months). In the other 11 CR patients, STIR abnormalities persisted at the time CR was achieved. Seven of them relapsed between 1 and 28 months (median, 3 months) after MR evaluation. Disease-free survival of patients with persistent abnormal STIR images was significantly shorter than that of patients with normal STIR images (P < 0.01). MR imaging of femoral marrow may predict outcome in adult patients with AML in CR.

References

Jul 1, 1991·British Journal of Haematology·J M BennettC Sultan
May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM J Keating
Sep 1, 1988·Radiology·J B Vogler, W A Murphy
Oct 1, 1988·Hematological Oncology·M A RichardsT A Lister
Mar 1, 1996·Baillière's Clinical Haematology·M A Sanz, A Sempere
Oct 1, 1996·Leukemia Research·A Biondi, A Rambaldi
Sep 30, 1999·The New England Journal of Medicine·B LöwenbergA Burnett

❮ Previous
Next ❯

Citations

Jul 5, 2003·International Journal of Hematology·Tetsuo MaedaYuji Matsuzawa
Jul 27, 2007·La Radiologia medica·O TamburriniP Martingano
May 7, 2008·Nuclear Medicine Communications·Yong LiuChunyan Chen
Mar 16, 2013·Polish journal of radiology·Anna Kwiatkowska-PamułaTomasz Adamczyk
Jun 14, 2005·European Journal of Radiology·Iris Nöbauer, Martin Uffmann
Apr 8, 2017·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Shannon M NavarroAaron J Schein
Sep 14, 2014·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Ewa ZiółkoMałgorzata Muc-Wierzgoń

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.